Resmed Inc (RMD)

Apr 21, 2025

ResMed Appoints Salli Schwartz as Chief Investor Relations Officer - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times

Apr 21, 2025

Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer | RMD Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Resmed (RMD) Names Salli Schwartz as New Chief Investor Relations Officer | RMD Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Resmed Strengthens Investor Relations: 20-Year Finance Expert from Illumina Takes Helm - Stock Titan

Apr 21, 2025

Apr 21, 2025

Assessing ResMed: Insights From 5 Financial Analysts - Benzinga

Apr 21, 2025

Apr 21, 2025

KeyBanc Adjusts ResMed Price Target to $269 From $280, Maintains Overweight Rating - marketscreener.com

Apr 21, 2025

Apr 21, 2025

KeyBanc Adjusts ResMed (RMD) Price Target Amid Economic Concerns | RMD Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

ResMed price target lowered to $268 from $280 at KeyBanc - TipRanks

Apr 21, 2025

Apr 17, 2025

Earnings Preview: What to Expect From ResMed’s Report - MSN

Apr 17, 2025

Apr 17, 2025

Fund Update: QRG CAPITAL MANAGEMENT, INC. added 47,913 shares of RESMED ($RMD) to their portfolio - Nasdaq

Apr 17, 2025

Apr 17, 2025

What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings - Yahoo Finance

Apr 17, 2025

Apr 17, 2025

ResMed Pushes Forward With Strong Growth In Sleep Apnea Market - Finimize

Apr 17, 2025

Apr 16, 2025

ResMed to Maintain Dominant Sleep Apnea Device Market Share, Expected to Deliver Net Cash Balance Sheet, Jarden Research Says - marketscreener.com

Apr 16, 2025

Apr 16, 2025

Mizuho Securities Adjusts ResMed Price Target to $265 From $280, Maintains Outperform Rating - marketscreener.com

Apr 16, 2025

Apr 16, 2025

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Apr 16, 2025

Apr 16, 2025

Jarden Research Adjusts Resmed's Price Target to AU$39.97 from AU$41.48, Keeps at Overweight - MarketScreener

Apr 16, 2025

Apr 15, 2025

Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance

Apr 15, 2025

Apr 14, 2025

Earnings Preview: What To Expect From ResMed’s Report - Barchart.com

Apr 14, 2025

Apr 12, 2025

ResMed (RMD) Placed on Citi's 90-Day Downside Catalyst Watch | R - GuruFocus

Apr 12, 2025

Apr 11, 2025

Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges - TipRanks

Apr 11, 2025

Apr 11, 2025

ResMed CFO Brett Sandercock sells $215,580 in stock By Investing.com - Investing.com Canada

Apr 11, 2025

Apr 11, 2025

Sonic and ResMed rejoin the Buy List - Intelligent Investor

Apr 11, 2025

Apr 10, 2025

ResMed CFO Brett Sandercock sells $215,580 in stock - Investing.com Australia

Apr 10, 2025

Apr 10, 2025

Why I'm taking a closer look at ResMed shares - The Motley Fool Australia

Apr 10, 2025

Apr 09, 2025

ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says - MarketScreener

Apr 09, 2025

Apr 09, 2025

ResMed CEO Michael Farrell sells $1.68 million in stock By Investing.com - Investing.com India

Apr 09, 2025

Apr 09, 2025

Resmed Insider Sold Shares Worth $1,680,699, According to a Recent SEC Filing - MarketScreener

Apr 09, 2025

Apr 09, 2025

ResMed CEO Michael Farrell sells $1.68 million in stock - Investing.com

Apr 09, 2025

Apr 08, 2025

ResMed CFO Sells Shares - MarketScreener

Apr 08, 2025

Apr 08, 2025

ResMed Inc. Officer Plans to Sell Shares Under Rule 144 - TipRanks

Apr 08, 2025

Apr 08, 2025

Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? - Nasdaq

Apr 08, 2025

Apr 07, 2025

Resmed launches HSAT across US - HME News

Apr 07, 2025

Apr 06, 2025

ResMed Inc Chairman Emeritus Adjusts Stock Holdings - TipRanks

Apr 06, 2025

Apr 05, 2025

ResMed Inc. (RMD): A Bull Case Theory - MSN

Apr 05, 2025

Apr 05, 2025

ResMed director Peter Farrell sells $439,480 in stock By Investing.com - Investing.com South Africa

Apr 05, 2025

Apr 04, 2025

ResMed director Peter Farrell sells $439,480 in stock - Investing.com

Apr 04, 2025

Apr 04, 2025

Resmed debuts wearable, at-home sleep apnea test - Fierce Biotech

Apr 04, 2025

Apr 04, 2025

RMD Stock Benefits From the Launch of NightOwl Across US - TradingView

Apr 04, 2025

Apr 04, 2025

Should I buy Fisher & Paykel or ResMed shares? - MSN

Apr 04, 2025

Apr 04, 2025

ResMed’s global general counsel sells $14,263 in stock By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 03, 2025

ResMed Launches Home Sleep Apnea Test Across US; Shares Fall 3% - MarketScreener

Apr 03, 2025

Apr 03, 2025

ResMed Inc Reports Changes in CDI and Securities Issuance - TipRanks

Apr 03, 2025

Apr 03, 2025

ResMed Inc’s General Counsel Reports Stock Transaction - TipRanks

Apr 03, 2025

Apr 03, 2025

ResMed launches at-home sleep apnea test - MassDevice

Apr 03, 2025

Apr 03, 2025

ResMed’s global general counsel sells $14,263 in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 50% gain - simplywall.st

Apr 03, 2025

Apr 03, 2025

Resmed Launches NightOwl Home Sleep Apnea Test - Medical Product Outsourcing

Apr 03, 2025